[1]林文科,吴吉芳,郑志昂.非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义[J].现代检验医学杂志,2018,33(02):46-50.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIN Wen-ke,WU Ji-fang,ZHENG Zhi-ang.Expression of Serum miR-141 and miR-224 in Patients with Non-Small Cell Lung Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):46-50.[doi:10.3969/j.issn.1671-7414.2018.02.001]
点击复制

非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年02期
页码:
46-50
栏目:
论著
出版日期:
2018-04-05

文章信息/Info

Title:
Expression of Serum miR-141 and miR-224 in Patients with Non-Small Cell Lung Cancer and Its Clinical Significance
文章编号:
1671-7414(2018)02-046-05
作者:
林文科; 吴吉芳; 郑志昂
海南省第三人民医院检验科,海南三亚 572000
Author(s):
LIN Wen-ke; WU Ji-fang; ZHENG Zhi-ang
Department of Clinical Laboratory, the Third People's Hospital of Hainan Province,Hainan Sanya 572000,China
关键词:
miR-141;  miR-224;  非小细胞肺癌;  临床意义
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.02.001
文献标志码:
A
摘要:
目的 探讨miR-141及miR-224在非小细胞肺癌(NSCLC)中的表达及其临床意义。方法 采用RT-PCR检测128例NSCLC患者,60例良性病变患者(良性组)和60例健康体检者(对照组)血清miR-141,miR-224及鳞状细胞癌相关抗原(SCC-Ag)表达水平,分析miR-141及miR-224表达水平与NSCLC临床病理特征的关系。应用ROC曲线评价miR-141,miR-224及SCC-Ag对NSCLC诊断的灵敏度和特异度,Pearson相关分析NSCLC患者血清miR-141与miR-224,SCC-Ag的相关性。结果 NSCLC组血清miR-141,miR-224及SCC-Ag表达水平均明显高于良性组和对照组[miR-141(2-ΔΔCt):2.56±0.48 vs 1.08±0.24和1.02±0.21; miR-224(2-ΔΔCt):3.94±0.82 vs 1.42±0.35和1.26±0.30; SCC-Ag(ng/ml):2.75±1.36 vs 0.64±0.47和0.52±0.24,F=8.719～11.573,均P<0.01]。在NSCLC患者中血清miR-141及miR-224表达水平与病理分期、病理分级及淋巴结转移相关(P<0.05)。ROC曲线分析显示,血清miR-141,miR-224及SCC-Ag(ng/ml)诊断NSCLC的最佳截值分别为1.84,2.85,2.03,三项联合诊断NSCLC的AUC(0.913)最大,其敏感度和特异度较好,分别为92.5%和82.7%。Pearson相关分析显示,血清miR-141与miR-224,SCC-Ag呈正相关(r=0.782,0.594,均P<0.01),血清miR-224与SCC-Ag呈正相关(r=0.594,P<0.01)。结论 血清miR-141及miR-224在NSCLC患者中明显上调,且与患者的临床病理特征相关,有望作为诊断NSCLC的新型生物标志物。
Abstract:
Abstract:Objective To investigate the expression of miR-141 and miR-224 in non-small cell lung cancer(NSCLC)and its clinical significance.Methods The levels of serum miR-141,miR-224 and squamous cell carcinoma associated antigen(SCC-Ag)were detected by RT-PCRin 128 patients with NSCLC,60 patients with benign lesions(benign group)and60 healthy subjects(control group).To analyze the relationship between the expression levels of miR-141 and miR-224 and the clinicopathological features ofNSCLC.The sensitivity and specificity of miR-141,miR-224 and SCC-Ag in thediagnosis of NSCLC were evaluated by ROC curve,and the correlation between serum miR-141 and miR-224,SCC-Ag were analyzed by Pearson correlation analysis in NSCLC patients.Results The levels of serum miR-141,miR-224 and SCC-Ag in NSCLC group were significantly higher than those in the benign group and the control group[miR-141(2-ΔΔCt):2.56±0.48 vs1.08±0.24 and 1.02±0.21,miR-224(2-ΔΔCt):3.94±0.82 vs 1.42±0.35 and 1.26±0.30,SCC-Ag(ng/ml):2.75±1.36 vs 0.64±0.47 and0.52±0.24,all P<0.01].In patients with NSCLC,the levels of serum miR-141 and miR-224 were correlated with pathological stage,pathological grade and lymph node metastasis(P<0.05).ROC curve analysis showed that the optimal cut-off values of serum miR-141,miR-224 and SCC-Ag(ng/ml)for diagnosisof NSCLC were 1.84,2.85 and 2.03,respectively.The AUC(0.913)of the three combined diagnosis of NSCLC was the largest,and the sensitivity and specificity were better,with 92.5% and 82.7%,respectively.Pearson correlation analysis showed that serum miR-141 were positively correlated with miR-224 and SCC-Ag(r=0.782,0.594,all P<0.01),and serum miR-224 was positively correlated with SCC-Ag(r=0.594,P<0.01).Conclusion Serum miR-141 and miR-224 are up-regulated in patients with NSCLC and are associated with clinicopathological features,and may be a new biomarker forthe diagnosis of NSCLC.

参考文献/References:

[1] Riquet M,Mordant P,Pricopi C,et al.A review of 250 ten-yearsurvivors after pneumonectomy for non-small-cell lung cancer[J].Eur J Cardiothorac Surg,2014,45(5):876-881.
[2] 孙红梅,陈文彰,燕丽香,等.血清肿瘤标志物对老年非小细胞肺癌检测的临床意义[J].中华老年多器官疾病杂志,2013,12(8):619-624. Sun HM,Chen WZ,Yan LX,et al.Clinical significance of serum tumormarkers in elderly patients with non-small cell lung cancer[J].Chinese Journal of Multiple Organ Diseases in the Elderly,2013,12(8):619-624.
[3] Han JG,Jiang YD,Zhang CH,et al.A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer[J].Ann SurgTreat Res,2017,92(2):55-66.
[4] Huang M,Wu L,Qin Y,et al.Anti-proliferative role and prognostic implication of miR-141 in gastric cancer[J].Am J Transl Res,2016,8(8):3549-3557.
[5] Zhu SH,He XC,Wang L.Correlation analysis of miR-200b,miR-200c,andmiR-141 with liver metastases in colorectal cancer patients[J].Eur Rev MedPharmacol Sci,2017,21(10):2357-2363.
[6] Cui R,Kim T,Fassan M,et al.MicroRNA-224 is implicated in lung cancerpathogenesis through targeting caspase-3 and caspase-7[J].Oncotarget,2015,6(26):21802-21815.
[7] Heβ AK,Weichert W,Budach V,et al.The role of microRNAs in head and neck squamous cell carcinoma:Biomarkers for prognosis,therapy selection, and novel therapeutics[J].HNO,2016,64(5):296-302.
[8] Cinpolat O,Unal ZN,Ismi O,et al.Comparison of microRNA profiles between benign and malignant salivary gland tumors in tissue,blood and saliva samples:a prospective,case-control study[J].Braz J Otorhinolaryngol,2017,83(3):276-284.
[9] Li W,Wang Y,Zhang Q,et al.MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer[J].PLoS One,2015,10(8):e0134220.
[10] Wang RJ,Zheng YH,Wang P,et al.Serum miR-125a-5p,miR-145and miR-146a as diagnostic biomarkers in non-small cell lung cancer[J].IntJ Clin Exp Pathol,2015,8(1):765-771.
[11] Mahdavinezhad A,Mousavi-Bahar SH,Poorolajal J,et al.Evaluation of miR-141,miR-200c,miR-30b expression and clinicopathological features of bladder cancer[J].Int J Mol Cell Med,2015,4(1):32-39.
[12] Ling H,Pickard K,Ivan C,et al.The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis[J].Gut,2015,65(6):977-989.
[13] Mei Z,He Y,Feng J,et al.MicroRNA-141 promotes the proliferation ofnon-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2[J].FEBS Lett,2014,588(17):3055-3061.
[14] Wang L,Liu W,Zhang YP,et al.The miR-224 promotes non-small cell lung cancer cell proliferation by directly targeting RASSF8[J].Eur Rev Med Pharmacol Sci,2017,21(14):3223-3231.
[15] Liu XG,Zhu WY,Huang YY,et al.High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer[J].Med Oncol,2012,29(2):618-626.
[16] 张洪岩,鲁继斌,杨 伟,等.miR-224,miR-135a在非小细胞肺癌中的表达及与临床病理的关系[J].现代肿瘤医学,2012,20(10):2057-2059. Zhang HY,Lu JB,Yang W,et al.Expression of miR-224 and miR-135a in non-small cell lung cancer and the relation with clinical pathology[J].ModernOncology,2012,20(10):2057-2059.
[17] Yang JS,Li BJ,Lu HW,et al.Serum miR-152,miR-148a,miR-148b,andmiR-21 as novel biomarkers in non-small cell lung cancer screening[J].Tumour Biol,2015,36(4):3035-3042.
[18] Si L,Tian H,Yue W,et al.Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer[J].Oncol Lett,2017,14(4):4325-4330.
[19] Wang C,Ding M,Xia M,et al.A Five-miRNA panel identified from a multicentric case-control study serves as a novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients[J].EBio Medicine,2015,2(10):1377-1385.

备注/Memo

备注/Memo:
作者简介:林文科(1980-),男,本科,主管技师,主要从事临床免疫肿瘤检验学研究,E-mail:415004372@qq.com。
更新日期/Last Update: 2018-04-16